Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients

Douglas T. Dieterich, Michael A. Poles, Edward A. Lew, Paul E. Mendez, Robert Murphy, Adrienne Addessi, Janet Teresa Holbrook, Katie Naughton, Dorothy N. Friedberg

Research output: Contribution to journalArticle

Abstract

Ten patients with AIDS and progressive cytomegalovirus disease were treated with ganciclovir and foscarnet concurrently. The patients had received ganciclovir and foscarnet monotherapy a median of 330 days before receiving combination therapy for a median of 80 days. Nine of the 10 patients responded to the combination. No electrolyte abnormalities were noted during combina-tion therapy, but rates of neutropenia (relative rate, combination vs. ganciclovir, 1.99; P = .229) and thrombocytopenia (relative rate, combination vs. ganciclovir, 1.53; P = .616) were higher with combination therapy than with either drug alone. The relative rate of anemia was significantly increased with combination therapy compared with monotherapy (relative rate, combination vs. ganciclovir, 2.69; P = .025). These data suggest that combination ganciclovir and foscarnet therapy after failure of either alone appears to be as effective as standard therapy with single agents. The rate of anemia with combination therapy was significantly greater than either agent alone, but no significant difference was noted among the other parameters of toxicity studied.

Original languageEnglish (US)
Pages (from-to)1184-1188
Number of pages5
JournalJournal of Infectious Diseases
Volume167
Issue number5
StatePublished - May 1993

Fingerprint

Foscarnet
Ganciclovir
Cytomegalovirus Infections
Acquired Immunodeficiency Syndrome
Therapeutics
Anemia
Neutropenia
Cytomegalovirus
Thrombocytopenia
Electrolytes

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Dieterich, D. T., Poles, M. A., Lew, E. A., Mendez, P. E., Murphy, R., Addessi, A., ... Friedberg, D. N. (1993). Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. Journal of Infectious Diseases, 167(5), 1184-1188.

Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. / Dieterich, Douglas T.; Poles, Michael A.; Lew, Edward A.; Mendez, Paul E.; Murphy, Robert; Addessi, Adrienne; Holbrook, Janet Teresa; Naughton, Katie; Friedberg, Dorothy N.

In: Journal of Infectious Diseases, Vol. 167, No. 5, 05.1993, p. 1184-1188.

Research output: Contribution to journalArticle

Dieterich, DT, Poles, MA, Lew, EA, Mendez, PE, Murphy, R, Addessi, A, Holbrook, JT, Naughton, K & Friedberg, DN 1993, 'Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients', Journal of Infectious Diseases, vol. 167, no. 5, pp. 1184-1188.
Dieterich DT, Poles MA, Lew EA, Mendez PE, Murphy R, Addessi A et al. Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. Journal of Infectious Diseases. 1993 May;167(5):1184-1188.
Dieterich, Douglas T. ; Poles, Michael A. ; Lew, Edward A. ; Mendez, Paul E. ; Murphy, Robert ; Addessi, Adrienne ; Holbrook, Janet Teresa ; Naughton, Katie ; Friedberg, Dorothy N. / Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. In: Journal of Infectious Diseases. 1993 ; Vol. 167, No. 5. pp. 1184-1188.
@article{c35710409ae246c4a749d1ce7e934011,
title = "Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients",
abstract = "Ten patients with AIDS and progressive cytomegalovirus disease were treated with ganciclovir and foscarnet concurrently. The patients had received ganciclovir and foscarnet monotherapy a median of 330 days before receiving combination therapy for a median of 80 days. Nine of the 10 patients responded to the combination. No electrolyte abnormalities were noted during combina-tion therapy, but rates of neutropenia (relative rate, combination vs. ganciclovir, 1.99; P = .229) and thrombocytopenia (relative rate, combination vs. ganciclovir, 1.53; P = .616) were higher with combination therapy than with either drug alone. The relative rate of anemia was significantly increased with combination therapy compared with monotherapy (relative rate, combination vs. ganciclovir, 2.69; P = .025). These data suggest that combination ganciclovir and foscarnet therapy after failure of either alone appears to be as effective as standard therapy with single agents. The rate of anemia with combination therapy was significantly greater than either agent alone, but no significant difference was noted among the other parameters of toxicity studied.",
author = "Dieterich, {Douglas T.} and Poles, {Michael A.} and Lew, {Edward A.} and Mendez, {Paul E.} and Robert Murphy and Adrienne Addessi and Holbrook, {Janet Teresa} and Katie Naughton and Friedberg, {Dorothy N.}",
year = "1993",
month = "5",
language = "English (US)",
volume = "167",
pages = "1184--1188",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients

AU - Dieterich, Douglas T.

AU - Poles, Michael A.

AU - Lew, Edward A.

AU - Mendez, Paul E.

AU - Murphy, Robert

AU - Addessi, Adrienne

AU - Holbrook, Janet Teresa

AU - Naughton, Katie

AU - Friedberg, Dorothy N.

PY - 1993/5

Y1 - 1993/5

N2 - Ten patients with AIDS and progressive cytomegalovirus disease were treated with ganciclovir and foscarnet concurrently. The patients had received ganciclovir and foscarnet monotherapy a median of 330 days before receiving combination therapy for a median of 80 days. Nine of the 10 patients responded to the combination. No electrolyte abnormalities were noted during combina-tion therapy, but rates of neutropenia (relative rate, combination vs. ganciclovir, 1.99; P = .229) and thrombocytopenia (relative rate, combination vs. ganciclovir, 1.53; P = .616) were higher with combination therapy than with either drug alone. The relative rate of anemia was significantly increased with combination therapy compared with monotherapy (relative rate, combination vs. ganciclovir, 2.69; P = .025). These data suggest that combination ganciclovir and foscarnet therapy after failure of either alone appears to be as effective as standard therapy with single agents. The rate of anemia with combination therapy was significantly greater than either agent alone, but no significant difference was noted among the other parameters of toxicity studied.

AB - Ten patients with AIDS and progressive cytomegalovirus disease were treated with ganciclovir and foscarnet concurrently. The patients had received ganciclovir and foscarnet monotherapy a median of 330 days before receiving combination therapy for a median of 80 days. Nine of the 10 patients responded to the combination. No electrolyte abnormalities were noted during combina-tion therapy, but rates of neutropenia (relative rate, combination vs. ganciclovir, 1.99; P = .229) and thrombocytopenia (relative rate, combination vs. ganciclovir, 1.53; P = .616) were higher with combination therapy than with either drug alone. The relative rate of anemia was significantly increased with combination therapy compared with monotherapy (relative rate, combination vs. ganciclovir, 2.69; P = .025). These data suggest that combination ganciclovir and foscarnet therapy after failure of either alone appears to be as effective as standard therapy with single agents. The rate of anemia with combination therapy was significantly greater than either agent alone, but no significant difference was noted among the other parameters of toxicity studied.

UR - http://www.scopus.com/inward/record.url?scp=0027408358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027408358&partnerID=8YFLogxK

M3 - Article

VL - 167

SP - 1184

EP - 1188

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -